Samodzielny Publiczny Szpital Kliniczny Nr 1 W Lublinie
- Address
- lock Available on a paid plan
Hematologic Malignancies and Myeloproliferative Disorders
At Samodzielny Publiczny Szpital Kliniczny Nr 1 W Lublinie, a large share of research focuses on blood cancers and related marrow disorders, including acute myeloid leukemia, chronic lymphocytic leukemia, lymphomas, multiple myeloma, and myelodysplastic syndromes. These studies are mainly designed to test new treatment approaches, compare them with current standards, and improve disease control and survival outcomes.
- New therapies for acute myeloid leukemia and treatment-resistant disease
- Studies in chronic lymphocytic leukemia and small lymphocytic lymphoma to improve response and progression control
- Research in multiple myeloma, lymphoma, and myeloproliferative neoplasms to evaluate effectiveness and long-term safety
These trials reflect a strong oncology program with a focus on better targeted treatment options and more durable disease management.
Ophthalmology and Eye Disease Research
The site also conducts clinical trials in eye diseases, especially conditions affecting vision and retinal health. Research includes neovascular age-related macular degeneration and uveitic macular edema, with the goal of evaluating new treatments that may help preserve or improve sight.
- Therapies aimed at protecting vision in retinal disease
- Studies for uveitic macular edema to improve swelling and visual outcomes
- Testing new approaches for age-related macular degeneration
Research in this field is centered on treatment effectiveness and better visual function for patients with chronic eye conditions.
Immune, Inflammatory, and Dermatologic Conditions
Clinical trial activity at the Lublin hospital includes a broad set of immune system and skin disease studies, such as atopic dermatitis, psoriasis, prurigo nodularis, epidermolysis bullosa simplex, and pyoderma gangrenosum. The purpose of these trials is to assess new therapies that may reduce symptoms, improve skin healing, and offer longer-lasting relief.
- New treatment options for atopic dermatitis and chronic itching disorders
- Research in psoriasis to measure skin improvement and symptom control
- Studies in rare skin and connective tissue diseases to support better symptom management
These investigations combine common inflammatory conditions with rare dermatologic diseases, broadening the site’s research profile.
Rare Blood Disorders and Complement-Related Diseases
This research center is active in hemic and lymphatic diseases beyond cancer, including paroxysmal nocturnal hemoglobinuria, primary immune thrombocytopenia, hemophilia, and systemic mastocytosis. The trials are focused on testing therapies that may reduce bleeding, improve blood counts, or help control abnormal immune and complement activity.
- Studies for paroxysmal nocturnal hemoglobinuria to evaluate new complement-targeting treatments
- Research in immune thrombocytopenia and hemophilia to lower bleeding risk
- Trials in systemic mastocytosis to examine symptom control and disease activity
These projects are especially important for patients with uncommon conditions that require highly specialized care.
Cardiovascular and Perioperative Research
Some trials at the site address cardiovascular disease and surgery-related complications, including atherosclerotic disease, vascular disease, myocardial injury after non-cardiac surgery, and hypotension in non-cardiac surgery. The aim is to improve prevention, perioperative safety, and outcomes for patients at risk of heart and circulation problems.
- Studies to reduce myocardial injury after surgery
- Research on vascular disease affecting carotid, peripheral, and abdominal arteries
- Trials evaluating ways to improve perioperative cardiovascular safety
These studies support better risk management around surgery and in patients with underlying cardiovascular conditions.
Solid Tumors and Gastrointestinal Cancer Studies
The hospital also participates in trials for several solid tumors, including gastric cancer, biliary tract cancer, endometrial cancer, ovarian cancer, and advanced metastatic solid tumors. Research in this area is aimed at improving treatment effectiveness, delaying recurrence, and extending survival with newer cancer therapies.
- Studies in gastric and gastroesophageal junction cancer to improve outcomes after treatment
- Research in biliary tract cancer and endometrial cancer to test novel combination therapies
- Trials in ovarian cancer and other advanced tumors to compare treatment benefit
These oncology studies show a broad commitment to both common and difficult-to-treat cancers.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 9 therapeutic areas and 15 of 128 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 127 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Samodzielny Publiczny Szpital Kliniczny Nr 1 W Lublinie
lock Showing 1 of 80 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 128 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 10 | Unknown | 2019-03-22 | 2025-03-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.